


January 26, 2011

Margaret Hamburg, M.D.  
Commissioner  
Food and Drug Administration  
Department of Health and Human Services  
10903 New Hampshire Avenue  
Silver Spring, MD 20993

Monica Knoll  
Executive Director / Founder / Survivor  
**CANCER101 Inc.**  
a 501(C)3 nonprofit organization

**Donations/Billing:** 429 East 52nd Street, Suite 25D, NY, NY 10022  
**Office/Packages:** 263 West 38<sup>th</sup> Street, 16<sup>th</sup> floor, NY, NY 10018  
T.646.638.2202 F.646.349.3035  
Mknoll@CANCER101.org www.CANCER101.org



**Board of Directors**

Myra Biblowit  
President

**The Breast Cancer  
Research Foundation**

Gregory Rodgers  
Partner

**Latham & Watkins**

Sarah Krug  
Director, Global Marketing  
**Pfizer**

Jeffrey Horn  
**Z-Medica Corporation**

Susan R. Silverman  
Senior Associate  
**NBBJ**

Garrett Bess  
President  
**Two River Pictures**

Deborah Axelrod, MD  
Director of Clinical  
Breast Services  
**NYU Langore Clinical  
Cancer Center**

Monica Knoll  
Executive Director  
**CANCER101 Inc.**

**Board of Advisors**

Lynne A. Blasi  
Director, Communications &  
Patient Information  
**American Society of  
Clinical Oncology**

Sharon Franz, RN  
President/Founder  
**National Coalition of  
Oncology Nurse Navigators**

Carolyn Messner  
DSW, LCSW-R, BCD  
Director of Education  
and Training  
**CancerCare, Inc.**

Migdalia Torres  
Program Director  
**Gilda's Club**

Robin Kleinman, RN  
Breast Nurse Specialist  
**NYU Langore Clinical  
Cancer Center**

Maryanne Juliano, RN  
**Beth Israel's  
Comprehensive  
Cancer Center**

Eloise Caggiano  
Director of Programs  
Survivor  
**Avon Foundation for Women**

Dear Dr. Hamburg:

CANCER101 is a national nonprofit that helps cancer patients and their caregivers to get organized and informed to fight their cancer. Although we do not provide treatment recommendations, we do help direct patients towards access to care.

I am writing to you today to share my deep concern about the FDA's decision to withdraw approval of Avastin (bevacizumab) as a treatment option for metastatic breast cancer patients.

I am a ten year breast cancer survivor and currently being treated for my third bout of ovarian cancer. I have been fortunate to receive Avastin for my ovarian cancer treatment and I am enjoying benefit from this drug.

It is my hope that the FDA grants Genentech a fair hearing and ultimately gives metastatic breast cancer patients the option to receive the same benefits I am currently receiving from Avastin.

It is vital that patients have as many treatment options as possible. Many metastatic breast cancer patients have and are, currently responding to Avastin. Please do not take away this option or insurance coverage from them or future patients.

Healthy wishes,

Monica Knoll

Executive Director/Founder/Four-time cancer survivor